Skip to main content

Minnesota biotech firm Vyriad raises $29.5 million for cancer-fighting viruses

Vyriad Inc., a company that's engineering cancer-killing viruses, announced Tuesday it raised $29.5 million in Series B funding.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.